Establishment of the Applied Therapeutics for Cancer Integrated Review Group

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

September 28, 2023

Issuing agencies

Health and Human Services DepartmentNational Institutes of Health

Full Text

<html>
<head>
<title>Federal Register, Volume 88 Issue 187 (Thursday, September 28, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 187 (Thursday, September 28, 2023)]
[Notices]
[Pages 66859-66860]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-21233]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Establishment of the Applied Therapeutics for Cancer Integrated 
Review Group

    Pursuant to the Federal Advisory Committee Act, as amended (5 
U.S.C. 1001-1014), the Director, National Institutes of Health (NIH) 
announces the establishment of the Applied Therapeutics for Cancer 
Integrated Review Group (IRG) as authorized by 42 U.S.C. 282(b)(16), 
section 402(b)(16) of the Public Health Service Act, as amended.
    The Director, NIH, has determined that the Applied Therapeutics for 
Cancer IRG is in the public interest in connection with the performance 
of duties imposed on NIH by law, and that these duties can best be 
performed through the advice and counsel of the committee.
    The committee provides advice and recommendations on funding 
applications and proposals, including but not limited to, the 
scientific and technical merit of applications for grants-in-aid for 
research, research training, or research-related grants and cooperative 
agreements, or contract proposals relating to scientific areas relevant 
to translational and clinical investigations that encompass cancer 
therapeutic development and cancer treatment.
    Inquiries may be directed to Claire Harris, Director, Office of 
Federal Advisory Committee Policy, Office of the Director, National 
Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, 
Maryland 20892 (Mail code 4875), Telephone (301) 496-2123, or 
<a href="/cdn-cgi/l/email-protection#286b4449415a4d0660495a5a415b68464140064f475e"><span class="__cf_email__" data-cfemail="4e0d222f273c2b60062f3c3c273d0e20272660292138">[email&#160;protected]</span></a>.


[[Page 66860]]


    Dated: September 21, 2023.
Lawrence A. Tabak,
Acting NIH Director, National Institutes of Health.
[FR Doc. 2023-21233 Filed 9-27-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on September 28, 2023.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.